The Use of Carbon Quantum Dot as Alternative of Stannous Chloride Application in Radiopharmaceutical Kits

Abstract EN

Even today, technetium-99m is a radionuclide choice for diagnostic in nuclear medicine.

The unique chemical and physical properties of technetium-99m make it suitable as an available radionuclide in many centers.

In this study, we examined the potential of CQD as a reducing agent in the MDP kit.

Citric acid-derived CQD was synthesized and confirmed by FT-IR, TEM, UV-Vis, XPS, and surface analysis.

No cytotoxicity was observed by the MTT assay.

They were reducing properties of the CQD confirmed by fluorescence microscopy.

The MDP kit is prepared by evaluating different parameters that affect the radiolabeling yield, including ligand, time, and CQD.

The optimum amount of each parameter is obtained by Box–Behnken software.

Finally, fluorescent spectroscopy, SPECT imaging, and biodistribution study showed that CQD reduces technetium-99m.

Accumulation of radiotracer in the femur showed that CQD could be used in a radiopharmaceutical kit.